---
document_datetime: 2025-04-07 14:35:27
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/fluenz-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: fluenz-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 1.7303927
conversion_datetime: 2025-12-27 21:01:37.784622
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Fluenz

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                       | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| II/0002              | Update of sections 4.2 and 4.4 of the SmPC to restrict the 2-dose schedule to children from 2 to 8 years of age who have not been vaccinated before, instead of children from 2 to 17 years of age who have not been vaccinated before, and to include a warning regarding the postponement of vaccinations | 27/02/2025                          | 28/03/2025                                  | SmPC, Labelling and PL           |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | with symptoms of an acute infection and in case of nasal blockage. In addition, the MAH took the opportunity to implement changes in sections 1, 2, 3, 4.1, 4.3, 4.4, 4.5, 4.6, 4.8, 4.9, 5.1, 6.1, 6.3, 6.5, 6.6 and 8 of the SmPC. The labelling and Package Leaflet are updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                     |            |     | in individuals   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------|
| WS/2796   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product | 30/01/2025 | n/a |                  |
| IG/1811/G | This was an application for a group of variations. B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 18/12/2024 | n/a |                  |

<div style=\"page-break-after: always\"></div>

|         | B.II.e.5.b - Change in pack size of the finished product - Deletion of a pack size(s)                                                                                                                        |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0004 | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                | 18/11/2024 | 28/03/2025 | Annex II               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0001 | B.I.a.5.a - Changes to the AS of a seasonal, prepandemic or pandemic vaccine against human influenza - Replacement of the strain(s) in a seasonal, prepandemic or a pandemic vaccine against human influenza | 11/07/2024 | 17/07/2024 | SmPC, Labelling and PL | As a result of this variation, Section 2 of the SmPC (qualitative and quantitative composition) has been updated to reflect the changes in influenza strains included in the 2024-2025 formulation. The SmPC section 2 has been updated as follows: A/Victoria/4897/2022 (H1N1)pdm09 - like strain (A/Norway/31694/2022, MEDI 369815) A/Thailand/8/2022 (H3N2) - like strain (A/Thailand/8/2022, MEDI 370626) B/Austria/1359417/2021 - like strain (B/Austria/1359417/2021, MEDI 355292) The Labelling, Package leaflet and Annex A have been updated accordingly. |